Elucidation of metabolism of the anticancer drug lenvatinib as a possible path to personalized therapy
The research team from the Laboratory of Molecular Carcinogenesis and Drug Development at our department has joined forces with colleagues from Mendel University in Brno to publish a study that consistently monitors possible pathways of metabolic oxidation of one of the tyrosine kinase inhibitors, lenvatinib (https://doi.org). /10.1016/j.biopha.2021.112391). Lenvatinib is a drug used in the treatment of several cancers and is also the most efficient tyrosine kinase inhibitor in the treatment of thyroid tumours.
Published Feb 02, 2022
